Not yet recruiting
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma
NCT07612787· Phase 1/2· Centre Hospitalier Universitaire de Saint Etienne· Source
Not yet recruiting
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
NCT07151586· Phase 2· UNICANCER· Source
Not yet recruiting
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer
NCT07241273· UNICANCER· Source
Contact: Jordan EBER, MD
Recruiting
Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma who progressed within 6 months of multimodality therapy for locally advanced disease.
2025-521437-88-00· Phase 2· Groupe Oncologie Radiotherapie Tete Cou· Source
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients
NCT07071844· Phase 2· GERCOR - Multidisciplinary Oncology Cooperative Group· Source
Contact: Meher BEN ABDELGHANI, MD
Recruiting
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as post transplantation maintenance therapy in patients with newly-diagnosed myeloma
2024-517325-43-00· Phase 2· Centre Hospitalier Universitaire De Nantes· Source
Active, not recruiting
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT06651229· Phase 1· Janssen Research & Development, LLC· Source
Recruiting
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
NCT06788756· Phase 2/3· Moleculin Biotech, Inc.· Source
Recruiting
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
NCT05973864· Phase 2· UNICANCER· Source
Recruiting
Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
NCT06450314· Phase 2· UNICANCER· Source
Not yet recruiting
Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients
NCT06477939· Phase 3· Institut de cancérologie Strasbourg Europe· Source
Contact: Manon VOEGELIN
Recruiting
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948· Phase 3· MedSIR· Source
Recruiting
Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial
NCT06126588· Phase 2· Central Hospital, Nancy, France· Source
Active, not recruiting
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324· Phase 3· Pfizer· Source
Recruiting
Prognostic Value of Measuring CtDNA in a Cohort of Patients With Stage III and IV Upper Aero-digestive Tract (UADT) Cancer , Treated With Curative RADiOtherapy With or Without Concomitant Treatment.
NCT06479070· Institut de Cancérologie de Lorraine· Source
Contact: SARTORI VS VALERIE
Recruiting
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
NCT06496581· Phase 3· UNICANCER· Source
Recruiting
Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of HER2+ cancer that has spread
2023-509566-38-00· Phase 1/2· Boehringer Ingelheim International GmbH· Source
Recruiting
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
NCT06481306· Phase 1/2· Bristol-Myers Squibb· Source
Active, not recruiting
Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01).
2023-508310-41-00· Phase 2· Centre Hospitalier Universitaire De Nantes· Source
Recruiting
FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and platinum as first line treatment in patients with large-cell neuroendocrine carcinomas (LCNECs) of the lung.
2023-506590-35-00· Phase 2· Centre Leon Berard· Source
Recruiting
FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
NCT06393816· Phase 2· Centre Leon Berard· Source
Contact: Roland SCHOTT, MD
Active, not recruiting
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma
2023-505436-35-00· Phase 3· Lysarc· Source
Recruiting
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
NCT06195709· Phase 3· Institut Curie· Source
Recruiting
Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy
NCT06107920· Phase 3· University Hospital, Rouen· Source
Recruiting
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
NCT06253611· Phase 2· GERCOR - Multidisciplinary Oncology Cooperative Group· Source
Contact: Meher BEN ABDELGHANI, MD
Recruiting
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
2023-503317-29-00· Phase 3· Institut Gustave Roussy· Source
Recruiting
CARE1 Pragmatic Clinical Trial
NCT06364631· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Philippe BARTHELEMY, MD
Recruiting
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
NCT05904119· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source
Recruiting
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
NCT06022003· Phase 2· French Innovative Leukemia Organisation· Source
Active, not recruiting
Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer
NCT06418126· Centre Paul Strauss· Source
Recruiting
Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
NCT05872204· Phase 2· Universitaire Ziekenhuizen KU Leuven· Source
Active, not recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608· Phase 3· Summit Therapeutics· Source
Recruiting
Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)
NCT06083103· Centre Paul Strauss· Source
Contact: Éric OUVRARD, MD
Recruiting
Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma
NCT05328024· Centre Paul Strauss· Source
Contact: Mickaël BURGY
Recruiting
Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
NCT05772481· Centre Paul Strauss· Source
Contact: Laure KUNTZ
Not yet recruiting
Thero2-01S22 in HER2-positive Breast Cancer
NCT05698186· Phase 3· Institut de cancérologie Strasbourg Europe· Source
Active, not recruiting
Efficacy Study on Quality of Life Criteria of a Digital Application on Any Cellphone (OnKO-Tips&Tricks) for Adolescents and Young Adults Diagnosed With Cancer
NCT05350631· University Hospital, Strasbourg, France· Source
Active, not recruiting
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
NCT05676931· Phase 2· Gilead Sciences· Source
Active, not recruiting
Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
NCT05219318· Phase 3· University Hospital, Bordeaux· Source
Active, not recruiting
A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide in combination with bortezomib and dexamethasone in people who have Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment.
2023-509859-13-00· Phase 3· Celgene Corp.· Source
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence
NCT05297617· Phase 2· Unicancer· Source
Recruiting
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
NCT05303532· Phase 3· Astrazeneca AB· Source
Active, not recruiting
AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma
NCT04881032· Phase 1/2· Centre Jean Perrin· Source
Recruiting
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05128825· Phase 2· K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc· Source
Recruiting
Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
NCT05183984· Phase 2· ARCAGY/ GINECO GROUP· Source
Active, not recruiting
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
NCT04802590· Phase 2· The Lymphoma Academic Research Organisation· Source
Recruiting
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
NCT04747054· Phase 3· UNICANCER· Source
Contact: Mickael BURGY, Dr (principal investigator)
Active, not recruiting
MSI/dMMR tumors in perioperative setting
NCT04795661· Phase 2· Centre Leon Berard· Source
Showing 50 of 75.